ISOVUE-M 200 Rx
Generic Name and Formulations:
Iopamidol 408mg/mL; soln for intrathecal administration; contains sodium 0.029mg, organically bound iodine 200mg per mL.
Indications for ISOVUE-M 200:
For intrathecal administration in adult neuroradiology inculding myelography (lumbar, thoracic, cervical, total columnar), and for contrast enhancement of computed tomographic (CECT) cisternography and ventriculography. For thoraco-lumbar myelography in children ≥2 years of age.
Adults and Children:
See literature regarding dosing based on procedure.
Concomitant corticosteroids. Repeat myelography in the event of technical failure. Significant local or systemic infections where bacteremia is likely.
Should be administered by professional trained in use of radiopaque agents in appropriate facilities with emergency treatment readily available. Increased intracranial pressure. Intracranial tumor. Abscess. Hematoma. History of convulsive disorder. Severe cardiovascular disease. Chronic alcoholism. Multiple sclerosis. Homozygous sickle cell disease. Multiple myeloma. Pheochromocytoma. Thyroid disorder. Diabetes. Patients with evidence of inadvertant intracranial entry of large or concentrated bolus of contrast medium: increased risk of seizures; consider prophylactic diazepam or barbiturate therapy. Direct intracisternal or ventricular administration for standard radiography: not recommended. Maintain elevation of head during procedure, on the stretcher, or in bed. Avoid excessive and active patient movement or straining. Maintain adequate hydration. Elderly. Pregnancy (Cat.B). Nursing mothers.
Concomitant drugs that lower seizure threshold (eg, phenothiazines, MAOIs, tricyclics, CNS stimulants, analeptics, major tranquilizers, antipsychotics): not recommended; discontinue 48hrs and for at least 24hrs post-procedure. May reduce iodine-binding capacity of thyroid tissue for up to 2 weeks.
Headache, GI upset, back pain, leg pain, neck pain, hypotension, others.
ISOVUE-M 200: Single dose vials (10mL, 20mL)—10; ISOVUE-M 300: Single dose vials (15mL)—10
Psychiatry Advisor Articles
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa
- Depression Profiles in Patients With Type 1 Diabetes vs Type 2 Diabetes
- Purpose, Questions of Social Interaction Lead Physicians to Delay Retirement
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Is Antidepressant Use in Pregnancy Tied to Psychiatric Disorders in Offspring?
- Cardiovascular Risk Management May Slow Neurocognitive Decline in HIV
- Maintenance rTMS for Treatment-Resistant Depression
- New Study Compares Opioid Dependence Relapse Treatments
- Increase Use of Nursing Home for Patients With Cognitive Impairment Category
- Venlafaxine XR Safe, Effective in Treating Generalized Anxiety Disorder